Small Stocks, Big Money™

ConnectM Technology Solutions (Nasdaq: CNTM) has gained a major institutional backer, as Win-Light Global Co. Ltd. disclosed a 6.9% stake in the company through a Schedule 13G SEC filing. This passive investment—totaling nearly 2 million shares—signals strong institutional confidence in ConnectM’s role at the forefront of the electrification economy. As a provider of cutting-edge energy intelligence solutions, ConnectM is driving the transition to all-electric heating, cooling, and mobility, positioning itself as a key player in the rapidly evolving modern energy landscape.

Atossa Therapeutics (Nasdaq: ATOS) is strategically advancing (Z)-endoxifen into metastatic breast cancer, aiming for a more efficient regulatory pathway to reach patients with high unmet needs. Clinical data has shown (Z)-endoxifen more than doubles progression-free survival compared to tamoxifen while maintaining a favorable safety profile. Beyond metastatic disease, Atossa is actively engaging with the FDA on additional indications, including breast cancer prevention and neoadjuvant therapy, where (Z)-endoxifen has demonstrated strong potential to reduce tumor proliferation and recurrence risks. This initiative reinforces Atossa’s commitment to delivering best-in-class breast cancer treatments and accelerating patient access to breakthrough therapies.

OS Therapies (NYSE American: OSTX) is taking a major step toward commercializing OST-HER2, its immunotherapy for osteosarcoma, by scheduling a Scientific Advice Meeting (SAM) with the UK’s MHRA in Q3 2025. The company aims to secure access to the Innovative Licensing and Access Pathway (ILAP), a move that could accelerate UK approval and pave the way for market entry across multiple countries. Positive Phase 2b data released in January 2025 showed statistically significant improvement in 12-month event-free survival (EFS), reinforcing OST-HER2’s potential to prevent metastatic recurrence in osteosarcoma patients. With Fast Track and Orphan Drug designations in the US and Europe, OS Therapies is aligning its global regulatory strategy to bring this first-in-class HER2-targeted immunotherapy to patients as quickly as possible.

Calidi Biotherapeutics (NYSE American: CLDI) achieved a major milestone with its RTNova platform, demonstrating the ability to systemically deliver transient gene therapy payloads directly to tumors. Preclinical results highlight successful immune activation and tumor eradication in metastatic cancer models, positioning RTNova as a potential game-changer for hard-to-treat cancers. The company’s novel vaccinia virus-based virotherapy not only targets and destroys tumors but also trains the immune system to fight future cancer cells. With this breakthrough, Calidi aims to expand its pipeline and explore strategic partnerships to advance next-generation immuno-oncology treatments.